Inositol lipid metabolism accompanies erythroid differentiation of K562 human leukemic cells.


:The role of hemin induction of K562 in inositol phospholipid metabolism has not been previously studied. K562 cells were induced to synthesize hemoglobin upon addition of bovine hemin to the culture media. The phospholipid content of K562 was determined before and after the addition of hemin. The results of this study demonstrated significant differences in the phosphoinositides between induced and non-induced cells. Phosphatidylinositol-4-phosphate (PIP) and phosphatidyl-inositol-4,5-bisphosphate (PIP2) levels increased upon induction, and remained above control levels. Phosphatidylinositol (PI) levels decreased 15 min after hemin addition, then increased to control levels by 1 h. From 2-8 h PI levels then remained depressed below control levels. These data suggest that hemoglobin induction in K562 cells occurs concomitantly with inositol phospholipid turnover.


Leuk Res


Leukemia research


Klette KL,Wanda PE





Has Abstract


1991-01-01 00:00:00












  • Effective cytotoxicity against human leukemias and chemotherapy-resistant leukemia cell lines by N-N-dimethylsphingosine.

    abstract::We evaluated the cytotoxicity of dimethylsphingosine (DMS) against four human leukemia cell lines: two acute (HL60 and a multi-drug resistance MDR-positive derivative HL60-dox) and two blast crisis chronic myelogenous leukemias (JFP1, from a treatment refractory patient and K562), and against blasts isolated from 11 l...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Jendiroba DB,Klostergaard J,Keyhani A,Pagliaro L,Freireich EJ

    更新日期:2002-03-01 00:00:00

  • Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.

    abstract::To improve the recovery rate of high-risk patients with acute promyelocytic leukemia (APL), we used all-trans retinoic acid (ATRA)/arsenic trioxide (ATO)/daunorubicin combination in remission induction, daunorubicin and cytarabine in consolidation, and ATRA/ATO/methotrexate ± 6-mercaptopurine in maintenance treatment ...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Huang H,Qin Y,Xu R,You X,Teng R,Yang L,Xu M,Liu H

    更新日期:2012-07-01 00:00:00

  • Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.

    abstract::Chronic myeloid leukaemia (CML) patients in chronic phase (CP) are currently treated with a standard dose of imatinib of 400mg/daily. However, once in complete cytogenetic remission (CCR) it is possible that some patients maintain this status with reduced dose of the drug. Here, we describe five cases of CML in late C...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Breccia M,Cannella L,Stefanizzi C,Santopietro M,De Cuia R,Diverio D,Alimena G

    更新日期:2009-05-01 00:00:00

  • Management of AML: who do we really cure?

    abstract::Most clinicians caring for patients with AML do not use the word "cure" casually, since for many patients diagnosed with AML, a state of cure or even of long term survival remains elusive. Analysis of prognostic factors may aid in defining the chance for cure in various AML subtypes, and improvements are required at a...

    journal_title:Leukemia research

    pub_type: 杂志文章,评审


    authors: Liesveld J

    更新日期:2012-12-01 00:00:00

  • The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells.

    abstract::AML progenitor cells (AML-PC) undergo significant apoptosis in response to the deacetylase inhibitor (DACi) LAQ824 and lose the replating capacity which was not observed with the DACi valproic acid. Treatment of normal hematopoietic progenitor cells (HPC) with LAQ824 resulted in (i) inhibition of differentiation, (ii)...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Schwarz K,Romanski A,Puccetti E,Wietbrauk S,Vogel A,Keller M,Scott JW,Serve H,Bug G

    更新日期:2011-01-01 00:00:00

  • Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.

    abstract::Acute myeloid leukemia (AML) is a heterogeneous disease. Until recently, treatment for patients with AML was limited to induction chemotherapy with cytarabine and anthracycline or hypomethylating agents, and, in some instances, allogeneic hematopoietic stem cell transplant. With the recent approval of new therapies-i....

    journal_title:Leukemia research

    pub_type: 杂志文章,评审


    authors: Talati C,Sweet K

    更新日期:2018-10-01 00:00:00

  • Near-tetraploid poorly differentiated acute myeloid leukemia M0 diagnosed by short-term cultures with a phorbol ester TPA.

    abstract::Leukemic blasts of two patients with acute leukemia exhibited similar characteristics. They were heterogeneous in size with a diameter of 14-30 microns in smears and unclassifiable by morphological, cytochemical, immunophenotypic and ultrastructural examinations. Cytogenetic examinations of both revealed a near-tetrap...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Lemez P,Jelínek J,Michalová K,Koubek K,Schwarz J,Malasková V,Rypácková B,Jirásek A,Brezinová J,Hrabánek J

    更新日期:1994-07-01 00:00:00

  • A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.

    abstract::Older patients with acute myelogenous leukemia (AML) have overexpression of P-glycoprotein (Pgp+), and this has been shown to correlate quantitatively with therapeutic outcome. Since Pgp-mediated efflux of cytotoxic drugs can be inhibited by the cyclosporine analogue, PSC 833, we investigated the use of this agent wit...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章


    authors: Chauncey TR,Rankin C,Anderson JE,Chen I,Kopecky KJ,Godwin JE,Kalaycio ME,Moore DF,Shurafa MS,Petersdorf SH,Kraut EH,Leith CP,Head DR,Luthardt FW,Willman CL,Appelbaum FR

    更新日期:2000-07-01 00:00:00

  • The clonogenic potential of selected CD34+ cells from patients with MDS appear preserved when tested ex vivo.

    abstract::Our aim was to examine in 17 patients with MDS the effects of PMA activated and non-activated autologous lymphocytes on selected bone marrow CD34+ progenitors, in dose response studies. We used a double layer culture technique. Compared with controls, there was no difference in the colony growth promoting capacity of ...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Davison GM,Novitzky N,Abdulla R

    更新日期:2011-09-01 00:00:00

  • Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.

    abstract::Aneuploidy is a very common prognostic factor in multiple myeloma (MM). Nonhyperdiploidy including near-tetraploidy (NT) is a poor prognostic indicator, compared to hyperdiploidy in multiple myeloma (MM). NT results from endoduplication of hypodiploidy. We report of a 55-year-old female patient diagnosed with advanced...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Yuan J,Shah R,Kulharya A,Ustun C

    更新日期:2010-07-01 00:00:00

  • Functional alterations of Lin-CD34+CD38+ cells in chronic myelomonocytic leukemia and on progression to acute leukemia.

    abstract::The functional behavior of hematopoietic stem cell (HSC) and progenitors in chronic myelomonocytic leukemia (CMML) and on disease progression is little known. We performed cell proliferation, apoptosis, hematopoietic colony forming/replating and differentiation potential studies in the purified subpopulations of Lin(-...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Sun Q,So CC,Yip SF,Wan TS,Ma SK,Chan LC

    更新日期:2008-09-01 00:00:00

  • Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib.

    abstract::MicroRNA (miRNA) is an important regulator of cellular proliferation, differentiation and death. Leukemia-specific signature of miRNAs suggests that epigenetic dysregulation of miRNAs is important for leukemogenesis. We focused on the role of DNA methylation of miR-203 which targets BCR-ABL1 mRNA. The microarray analy...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Shibuta T,Honda E,Shiotsu H,Tanaka Y,Vellasamy S,Shiratsuchi M,Umemura T

    更新日期:2013-10-01 00:00:00

  • Mesenchymal stem cells derived from multiple myeloma patients protect against chemotherapy through autophagy-dependent activation of NF-κB signaling.

    abstract::Chemotherapy resistance has been considered as a major problem for multiple myeloma (MM) treatment and bone marrow microenvironment plays a crucial role in the MM progression and chemoresistance. Recent studies reported that bone marrow mesenchymal stem cells derived from MM patients (MM-MSCs) revealed various charact...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Yang H,Zheng Y,Zhang Y,Cao Z,Jiang Y

    更新日期:2017-09-01 00:00:00

  • Ricin fusion toxin targeted to the human granulocyte-macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells.

    abstract::Treatment failure of patients with acute myelogenous leukemia (AML) is frequently due to the development of multidrug resistance phenotype blasts. We have expressed a fusion protein consisting of human granulocyte-macrophage colony stimulating factor (GMCSF) fused to the N-terminus of a lectin-deficient ricin toxin B ...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Burbage C,Tagge EP,Harris B,Hall P,Fu T,Willingham MC,Frankel AE

    更新日期:1997-07-01 00:00:00

  • Cytotoxic responses to BLV tax oncoprotein do not prevent leukemogenesis in sheep.

    abstract::Delta retrovirus-mediated leukemogenesis is dependent on the oncogenic potential of Tax. It is not clear, however, whether Tax-specific immune responses play a role in leukemia onset and progression. Using the BLV-associated leukemia model in sheep, we found that Tax-specific cytotoxic responses induced by DNA immuniz...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Van den Broeke A,Oumouna M,Beskorwayne T,Szynal M,Cleuter Y,Babiuk S,Bagnis C,Martiat P,Burny A,Griebel P

    更新日期:2010-12-01 00:00:00

  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.

    abstract::There is a significant need for improved therapeutics in older patients with acute leukemia. Camidanlumab tesirine is an antibody-drug conjugate against CD25, an antigen expressed in several malignancies, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This open-label, dose-escalation an...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究


    authors: Goldberg AD,Atallah E,Rizzieri D,Walter RB,Chung KY,Spira A,Stock W,Tallman MS,Cruz HG,Boni J,Havenith KEG,Chao G,Feingold JM,Wuerthner J,Solh M

    更新日期:2020-08-01 00:00:00

  • Expression of a 215,000-dalton nuclear envelope protein decreases during cell maturation.

    abstract::The monoclonal antibody AGF2.3 identifies a nuclear envelope protein expressed at high levels in most transformed cell lines and weakly expressed in or absent from normal tissues and primary cell cultures. Here we report that expression of AGF2.3 antigen relates to the maturation status of cells. When HL60 cells were ...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Brown G,Bunce CM,Johnson GD,Lord JM

    更新日期:1986-01-01 00:00:00

  • The role of thiotepa in autologous bone marrow transplantation for acute leukemia.

    abstract::Post-transplant leukemic relapse remains the major problem following autologous bone marrow transplantation (ABMT). One possible approach to reducing the relapse rate is to intensify pre-transplant conditioning. Thiotepa (TTP) is an alkylating agent that has been used mainly in breast and ovarian cancer with 20-50% re...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章


    authors: Nagler A,Finlander R,Or R,Naparstek E,Varadi G,Slavin S

    更新日期:1998-11-01 00:00:00

  • Clinical consequences of 2'-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia.

    abstract::Five patients from the Kyushu area in Japan with adult T-cell leukaemia (ATL) refractory to conventional chemotherapeutic agents were treated with 5 mg/m2 of the adenosine deaminase inhibitor, 2'-deoxycoformycin (DCF), intravenously (i.v.) for 3 consecutive days, followed by 5 mg/m2 i.v. weekly. Two patients showed a ...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Yamaguchi K,Yul LS,Oda T,Maeda Y,Ishii M,Fujita K,Kagiyama S,Nagai K,Suzuki H,Takatsuki K

    更新日期:1986-01-01 00:00:00

  • Submicroscopic deletions in an acute myeloid leukemia case with a four-way t(8;11;16;21).

    abstract::The t(8;21)(q22;q22) rearrangement is observed in about 15% of acute myelocitic leukemia (AML) cases, while variant t(8;21) translocations are detected in 6-10% of AML patients positive for the 5'RUNX1/3'CBFA2T1 fusion gene. We report a detailed molecular cytogenetic analysis of a four-way variant t(8;11;16;21)(q22;q1...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Albano F,Specchia G,Anelli L,Liso A,Zagaria A,Santoro A,Mirto S,Liso V,Rocchi M

    更新日期:2005-07-01 00:00:00

  • Less apoptosis in patients with 5q-syndrome than in patients with refractory anemia.

    abstract::The WHO classification of hematological malignancies includes 5q-syndrome as a separate category within myelodysplastic syndromes (MDS). Clinically, patients with 5q-syndrome have a milder disease than patients with other MDS. The basis for this difference is not known. Identifying 5q-syndrome can be difficult because...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Washington LT,Jilani I,Estey E,Albitar M

    更新日期:2002-10-01 00:00:00

  • Kappa light chain gene rearrangement in a T-cell lymphoma.

    abstract::Forty-three patients were studied to determine whether light chain gene rearrangements may occur in hematopoietic cells not pertaining to the B-lineage. In only one patient, affected by T-cell lymphoblastic lymphoma, one kappa light chain allele was rearranged. Neither at the protein level nor at the RNA level the rea...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Moretti L,Mariano MT,Donelli A,Montagnani G,Sarti M,Grantini M,Di Prisco U,Torelli U,Narni F

    更新日期:1991-01-01 00:00:00

  • Indomethacin induces apoptosis and inhibits proliferation in chronic myeloid leukemia cells.

    abstract::A nonsteroidal anti-inflammatory drug (NSAID)--indomethacin (IN), was found to induce apoptosis and inhibit proliferation of K562 cells and primary culture bone marrow cells from six chronic myelogenous leukemia (CML) patients. IN induced cells apoptosis and inhibited cells proliferation in a dose-and time-dependent m...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Zhang G,Tu C,Zhang G,Zhou G,Zheng W

    更新日期:2000-05-01 00:00:00

  • MiR-15a/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma.

    abstract::miRNAs have been reported to be involved in the pathogenesis of many cancers. In this article, we investigated the role and the mechanisms of miR-15a/16 in the pathogenesis of multiple myeloma (MM). We found that miR-15a/16 was down-regulated in bone marrow-derived mononuclear cells (BM-MNCs) of newly diagnosed patien...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Li Y,Zhang B,Li W,Wang L,Yan Z,Li H,Yao Y,Yao R,Xu K,Li Z

    更新日期:2016-10-01 00:00:00

  • Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents.

    abstract::We used a novel high-throughput drug screening assay, based on Luminex technology, to identify anti-myeloma agents capable of inhibiting cytokines and growth factors essential for multiple myeloma (MM) from a chemical library of 1120 compounds provided by MMRF. Tetracycline derivatives inhibited MM cell proliferation ...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Feng R,Rios JA,Onishi T,Lokshin A,Gorelik E,Lentzsch S

    更新日期:2010-07-01 00:00:00

  • Identification of interleukin 6 as a synergistic factor for the differentiation-inducing effect of TNF on leukemic ML-1 cells.

    abstract::Recombinant TNF was capable of inducing differentiation of human leukemic ML-1 cells in the monocytic pathway. Recombinant interleukin 6 did not have the activity but it could significantly increase the activity of recombinant TNF. Both of these molecules were found to play a similar role in PWM-induced conditioned me...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Samal B,Stearns G,Crandall C,Arakawa T,Boone T

    更新日期:1990-01-01 00:00:00

  • Improving risk-stratification of patients with chronic lymphocytic leukemia using multivariate patient similarity networks.

    abstract:BACKGROUND:Better risk-stratification of patients with chronic lymphocytic leukemia (CLL) and identification of subsets of ultra-high-risk (HR)-CLL patients are crucial in the contemporary era of an expanded therapeutic armamentarium for CLL. METHODS:A multivariate patient similarity network and clustering was applied...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Turcsanyi P,Kriegova E,Kudelka M,Radvansky M,Kruzova L,Urbanova R,Schneiderova P,Urbankova H,Papajik T

    更新日期:2019-04-01 00:00:00

  • Stem-cell leukemia: p53 deficiency mediated suppression of leukemic differentiation in C3H/He myeloid leukemia.

    abstract::C3H/He mice produce myeloid leukemias after whole body irradiation of 1-3Gy as compared with non-irradiated controls that produce fewer than 1% of leukemia [Radiatiton Research 127 (1991) 146]. Thus, p53-deficient C57BL/6 strain, a malignant lymphoma prone, was crossed back into C3H/He strain. Lethally irradiated wild...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Yoshida K,Aizawa S,Watanabe K,Hirabayashi Y,Inoue T

    更新日期:2002-12-01 00:00:00

  • Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C.

    abstract::Thirty patients with high-risk myelodysplastic syndrome, defined as > 5% bone marrow blasts, were treated with a combination of oral all-trans-retinoic acid (45 mg/m2 daily) and subcutaneous AraC (10 mg/m2) on days 1-14 of each 28-35 day cycle repeated for 2-6 cycles. Complete remission lasting 9, 12, and 15 months wa...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章


    authors: Letendre L,Noel P,White WL,Tefferi A,Litzow MR,Li CY,Schroeder G

    更新日期:1999-09-01 00:00:00

  • Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT).

    abstract::We investigated the role of Src family kinases (SFKs) in the regulation of STAT activation in myeloid leukemia cells. Two of 6 AML cell lines displayed constitutive STAT5 activation, whereas four cell lines had constitutive SFK activity. Treatment with the SFK inhibitors suppressed STAT5 activation and decreased viabi...

    journal_title:Leukemia research

    pub_type: 杂志文章


    authors: Ozawa Y,Williams AH,Estes ML,Matsushita N,Boschelli F,Jove R,List AF

    更新日期:2008-06-01 00:00:00